

Membership of cirrhosis guideline Committee

The Committee will operate as an advisory Committee to NICE’s Board, developing a guideline on cirrhosis.

The terms of reference and standing orders for the Committee can be found in [appendix D of Developing NICE guidelines: the manual](#).

Membership list

Name	Job Title, Organisation
Chair	
Phillip Harrison	Consultant Hepatologist, King’s College Hospital
Core members / Members	
Iain Brew	General Practitioner, Leeds Community Healthcare NHS Trust
Andrew Fowell	Consultant Hepatologist, Portsmouth Hospitals NHS Trust
Lynda Greenslade	Clinical Nurse Specialist in Hepatology, Royal Free London Foundation Trust
Mark Hudson	Consultant Hepatologist, Newcastle Hospitals NHS Trust
Andrew Langford	Patient/Carer Member
Susan McRae	Patient/Carer Member
Marsha Morgan	Principal Research Associate and Honorary Consultant Physician, UCL Institute for Liver and Digestive Health, University College London Medical School
Gerri Mortimore	Lead CNS Liver, Derby Hospitals NHS Foundation Trust
Valerie Ross	Lead Pharmacist Hepatology, Barts Health NHS Trust
Topic expert members	
David Fitzmaurice	Professor of Primary Care, University of Birmingham
John O’Grady	Professor of Hepatology, King’s College Hospital
Phillip Johnson	Professor of Oncology, University of Liverpool & Clatterbridge Cancer Centre

Committee membership list – cirrhosis guideline Committee

Rachel Pryke	General Practitioner Partner, Winyates Health Centre, Redditch
Roy Sherwood	Professor of Clinical Biochemistry, King's College London

Date last reviewed: 06/07/2016

Declaration of Interests

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Iain Brew	General Practitioner, Leeds Community Healthcare NHS Trust	At recruitment: GP with special interest in hepatitis C.	Personal non-financial specific	Declare and participate
		At recruitment: Contributor to the APPHG Report on Liver Disease 2014.	Personal non-financial specific	Declare and participate
		At recruitment: Has received honoraria, travel and accommodation expenses from Janssen for attending, speaking at and chairing meetings about treatment of hepatitis C.	Personal financial non-specific	Declare and participate
		At recruitment: Has received honoraria, travel and accommodation expenses from AbbVie for attending, speaking at and chairing meetings about treatment of hepatitis C.	Personal financial non-specific	Declare and participate
		At recruitment: I have received payments (£200 x 2) for articles on liver health published in the British Journal of Primary Care Nursing.	Personal financial non-specific	Declare and participate
		11/07/2014: Apologies received.	Nil	Nil
04/09/2014:	Personal	Declare and		

Committee membership list – cirrhosis guideline Committee

		<p>Payment for attending and chairing advisory boards for Janssen and AbbVie.</p> <p>17/10/2014: Janssen paid for attendance at BASL in Newcastle (October 2014)</p> <p>26/11/2014: No new DOI.</p> <p>21/01/2015: No new DOI.</p> <p>18/02/2015: Delivered a lecture on hepatitis C treatment in prisons for Gilead: honorarium payable.</p> <p>18/02/2015: Conference and travel costs covered by Janssen for a hepatitis C meeting.</p> <p>26/03/2015: No new DOI.</p> <p>30/04/2015: No new DOI.</p> <p>25/06/2015: AbbVie paying honorarium and travel costs 10 July meeting about hepatitis C treatments.</p> <p>29/07/2015: Apologies received.</p> <p>02/09/2015: No new DOI.</p> <p>14/03/2016: No new DOI.</p>	<p>financial non-specific</p> <p>Personal financial non-specific</p> <p>Nil</p> <p>Nil</p> <p>Personal financial non-specific</p> <p>Personal financial non-specific</p> <p>Nil</p> <p>Nil</p> <p>Personal financial non-specific</p> <p>Nil</p> <p>Nil</p>	<p>participate</p> <p>Declare and participate</p> <p>Nil</p> <p>Nil</p> <p>Declare and participate</p> <p>Declare and participate</p> <p>Nil</p> <p>Nil</p> <p>Declare and participate</p> <p>Nil</p> <p>Nil</p> <p>Nil</p>
David Fitzmaurice	Professor of Primary Care, University of Birmingham	<p>15/01/2015: None</p> <p>21/01/2016: No new DOI.</p>	<p>Nil</p> <p>Nil</p>	<p>Nil</p> <p>Nil</p>
Andrew Fowell	Consultant Hepatologist, Portsmouth	Recruitment: none declared.	Nil	Declare and participate

Committee membership list – cirrhosis guideline Committee

	Hospitals NHS Trust	<p>11/07/2014: No new DOI.</p> <p>04/09/2014: Received travel expenses from Janssen to attend a conference.</p> <p>Secretary of the Wessex Gut Club (Gastroenterological society). Has responsibility for organising twice yearly meetings. All money paid is directly to the Gut Club. Meetings took place on the following dates and pharma company funding is outlined: November 2013: Roche, Janssen, AbbVie, Gilead, Ferring, Falk, Novartis, Vifor, Pentax July 2014: Janssen, Gilead, Falk, Tillots, Vifor, Ferring November 2014: dealt with organising programme of speakers only.</p>	<p>Nil</p> <p>Personal financial non-specific</p> <p>Non-personal financial non-specific</p> <p>Roche: Non-personal financial specific</p>	<p>Declare and participate</p> <p>Declare and participate</p> <p>Declare and participate</p> <p>Declare and participate</p>
		17/10/2014: No new DOI.	Nil	Nil
		26/11/2014: No new DOI.	Nil	Nil
		21/01/2015: No new DOI.	Nil	Nil
		18/02/2015: No new DOI.	Nil	Nil

Committee membership list – cirrhosis guideline Committee

		<p>DOI.</p> <p>26/03/2015: Received travel and accommodation from Janssen to attend a conference in 2015.</p> <p>30/04/2015: No new DOI.</p> <p>25/06/2015: No new DOI.</p> <p>29/07/2015: Organised speakers for the Wessex Gut Club meeting in July 2015.</p> <p>02/09/2015: Organising speakers for the Wessex Gut Club meeting taking place in November 2015.</p> <p>14/03/2016: Accepted sponsorship from Gilead to attend the EASL International Liver Conference, April 2016: economy class travel, hotel accommodation and meeting registration fee.</p>	<p>Personal financial non-specific</p> <p>Nil</p> <p>Nil</p> <p>Personal non-financial non-specific</p> <p>Personal non-financial non-specific</p> <p>Personal financial non-specific</p>	<p>Declare and participate</p> <p>Nil</p> <p>Nil</p> <p>Declare and participate</p> <p>Declare and participate</p> <p>Nil</p>
Lynda Greenslade	Clinical Nurse Specialist in Hepatology, Royal Free London Foundation Trust	<p>11/07/2014: Norgine Advisory Board Member: 2/3 December 2013: accommodation and subsistence</p> <p>8 April 2014: accommodation and subsistence</p> <p>Advisory Board calls: 22 and 29 June 2014</p> <p>11/07/2014: Norgine Educational</p>	<p>Personal financial specific</p> <p>Personal financial specific</p>	<p>Withdraw from question relating to acute hepatic encephalopathy</p> <p>Withdraw from question relating to</p>

Committee membership list – cirrhosis guideline Committee

	<p>Meeting Committee Member: telephone call 14 and 26 November 2013, 16 December 2013, 7 and 12 May 2014. One-off payment for being part of the education committee and a talk.</p>		acute hepatic encephalopathy
	<p>11/07/2014: Norgine-sponsored liver nurses meeting 6 and 7 June 2014: accommodation and subsistence. Payment received for chairing one session and giving one talk.</p>	Personal financial specific	Withdraw from question relating to acute hepatic encephalopathy
	<p>11/07/2014: Payment received from speaking at the (Norgine-sponsored) Royal College of Nursing congress on 18 June 2014.</p>	Personal financial specific	Withdraw from question relating to acute hepatic encephalopathy
	<p>11/07/2014: Data on hepatic encephalopathy patients from Royal Free Foundation Trust given to advisory board meeting for real world data, for Norgine.</p>	Personal non-financial specific	Withdraw from question relating to acute hepatic encephalopathy
	<p>11/07/2014: Sponsored by Norgine to go to the European Association for the Study of the Liver conference.</p>	Personal financial specific	Withdraw from question relating to acute hepatic encephalopathy
	<p>04/09/2014: Janssen paid for standard travel expenses to attend BASL Liver meeting.</p>	Personal financial non-specific	Declare and participate

Committee membership list – cirrhosis guideline Committee

		17/10/2014: No new DOI.	Nil	Nil
		26/11/2014: Attended Norgine-sponsored Liver Nurses Educational Meeting on 21 and 22 November 2014. On the education board, chaired some sessions and gave a talk; accommodation and subsistence provided.	Personal financial specific	Withdraw from question relating to acute hepatic encephalopathy
		21/01/2015: No new DOI.	Nil	Nil
		18/02/2015: No new DOI.	Nil	Nil
		26/03/2015: Funding for travel and accommodation received from Janssen to attend the European Association for the Study of the Liver conference 2015.	Personal financial non-specific	Declare and participate
		30/04/2015: No new DOI.	Nil	Nil
		25/06/2015: Attended Norgine-sponsored liver nurses meeting 15 and 16 May 2015: accommodation and subsistence. Payment for chairing one session and giving one talk.	Personal financial non-specific	Declare and participate
		29/07/2015: No new DOI.	Nil	Nil
		02/09/2015: No new DOI.	Nil	Nil
		14/03/2016: No new DOI.	Nil	Nil
Phillip Harrison	Consultant Hepatologist, King's	07/01/2014: None declared.	Nil	Nil

Committee membership list – cirrhosis guideline Committee

	College Hospital	11/07/2014: Nil 04/09/2014: Nil 17/10/2014: Nil 26/11/2014: Nil 21/01/2015: Nil 18/02/2015: Nil 26/03/2015: Nil 30/04/2015: Nil 25/06/2015: Nil 29/07/2015: Nil 02/09/2015: Nil 14/03/2016: Nil	Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil	Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil
Mark Hudson	Consultant Hepatologist, Newcastle Hospitals NHS Trust	At recruitment: Has advised Astellas on immunosuppression within the last year. At recruitment: Has advised Novartis on immunosuppression within the last year. At recruitment: Has advised Norgine on rifaximin within the last year. At recruitment: I am the Co-Chief Investigator on the impact of rifaximin- α on the NHS Hospital Resource use associated with the management of patients with Hepatic Encephalopathy: A retrospective observational study (IMPRESS). The IMPRESS study is a multicentre CLRN Portfolio study funded by Norgine. The trial has been in development since April 2014.	Personal financial non-specific Personal financial non-specific Personal financial specific Personal non-financial specific	Declare and participate Declare and participate Withdraw from question relating to acute hepatic encephalopathy Withdraw from question relating to acute hepatic encephalopathy

Committee membership list – cirrhosis guideline Committee

	Has received no payment or personal financial gain from the IMPRESS study.		
	11/07/2014: No new DOI.	Nil	Nil
	04/09/2014: No new DOI.	Nil	Nil
	17/10/2014: Attended a Norgine advisory board on rifaximin. Received a payment on 27 October 2014 for attending a Norgine advisory board to discuss the natural history of hepatic encephalopathy.	Personal financial specific	Withdraw from question relating to acute hepatic encephalopathy
	26/11/2014: No new DOI.	Nil	Nil
	21/01/2015: No new DOI.	Nil	Nil
	18/02/2015: No new DOI.	Nil	Nil
	26/03/2015: No new DOI.	Nil	Nil
	30/04/2015: No new DOI.	Nil	Nil
	25/06/2015: Speaker for Norgine at a meeting (2 June) on hepatic encephalopathy.	Personal financial specific	Declare and participate Declare and participate
	Chaired a session for Abbvie on 23 June relating to viral hepatitis.	Personal financial specific	
	29/07/2015: Novartis provided travel support to attend the International Liver Transplant Society meeting in Chicago from 7 to 11 July 2015.	Personal financial non-specific	Declare and participate
	02/09/2015: No new DOI.	Nil	Nil

Committee membership list – cirrhosis guideline Committee

		DOI. 14/03/2016: Apologies received.	Nil	Nil
Phillip Johnson	Professor of Oncology, University of Liverpool & Clatterbridge Cancer Centre	At recruitment: One-off advisory board meetings: Astellas (13 February 2014) Boehringer-Ingelheim (17 October 2014). At recruitment: funding received from Bayer Healthcare for 1-year support of research nurse/data manager from September 2014 to August 2015. 26/03/2015: Travel expenses from Wako Life Sciences to attend an American Association for the Study of Liver Diseases meeting.	Personal financial non-specific Non-personal financial non-specific Personal financial specific	Declare and participate (as a co-optee) Declare and participate (as a co-optee) Declare and participate (as a co-optee)
Andrew Langford	Patient/Carer Member	At recruitment: In the last year, the British Liver Trust have received: <ul style="list-style-type: none"> • funding from Roche for the development of case studies on "Confronting the silent epidemic: a critical review of hepatitis C management in the UK" a Hepatitis Awareness Leading Outcomes report (29 April 2013) • funding from Astellas as support from 2013–2014 (15 	Non-personal financial non-specific	Declare and participate

Committee membership list – cirrhosis guideline Committee

		<p>May 2013)</p> <ul style="list-style-type: none"> • funding from Janssen for RCGP accreditation (2 August 2014) • funding from Lundbeck for PR support • funding from AbbVie as honoraria (panel) • funding from Galderma as honoraria (NMSC) • funding from Janssen as honoraria (EASL) <p>11/07/2014: Apologies received.</p> <p>04/09/2014: British Liver Trust press release regarding rifaximin for hepatic encephalopathy.</p> <p>17/10/2014: No new DOI.</p> <p>26/11/2014: Apologies received.</p> <p>21/01/2015: No new DOI.</p> <p>18/02/2015: Apologies received.</p> <p>26/03/2015: No new DOI.</p> <p>30/04/2015: The British Liver Trust was gifted a Fibroscan machine by Norgine.</p> <p>25/06/2015: No new DOI.</p> <p>29/07/2015: No new DOI.</p> <p>02/09/2015: No new DOI.</p> <p>14/03/2016: No new DOI.</p>		
Susan	Patient/Carer	At recruitment:	Personal	Declare and

Committee membership list – cirrhosis guideline Committee

McRae	Member	<p>Employed by the Hepatitis C Trust, the UK HCV patient charity.</p> <p>11/07/2014: No new DOI.</p> <p>04/09/2014: No new DOI.</p> <p>17/10/2014: No new DOI.</p> <p>26/11/2014: No new DOI.</p> <p>21/01/2015: No new DOI.</p> <p>18/02/2015: No new DOI.</p> <p>26/03/2015: No new DOI.</p> <p>30/04/2015: No new DOI.</p> <p>25/06/2015: No new DOI.</p> <p>29/07/2015: Expenses paid for judging quality in care hepatitis C 2015 entries, organised by PMGroup with funding from Bristol-Myers Squibb and Gilead.</p> <p>02/09/2015: No new DOI.</p> <p>14/03/2016: Apologies received.</p>	<p>non-financial specific</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Personal financial non-specific</p> <p>Nil</p> <p>Nil</p>	<p>participate</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Declare and participate</p> <p>Nil</p> <p>Nil</p>
Marsha Morgan	Principal Research Associate and Honorary Consultant Physician, UCL Institute for Liver and Digestive Health, University College London	At recruitment: Has taken part in symposia both in the UK and abroad on aspects of alcohol dependence, alcohol-related liver disease, nutrition in chronic liver disease and hepatic encephalopathy.	Personal financial non-specific	Declare and participate

Committee membership list – cirrhosis guideline Committee

	Medical School	<p>At recruitment: A member of the Advisory board of the Institute of Alcohol Studies. Receive an annual stipend used to support research activities.</p> <p>11/07/2014: No new DOI.</p> <p>04/09/2014: No new DOI.</p> <p>17/10/2014: Author of Cochrane review currently in development on hepatic encephalopathy.</p> <p>26/11/2014: No new DOI.</p> <p>21/01/2015: No new DOI.</p> <p>18/02/2015: No new DOI.</p> <p>26/03/2015: No new DOI.</p> <p>30/04/2015: No new DOI.</p> <p>25/06/2015: No new DOI.</p> <p>29/07/2015: Apologies received.</p> <p>02/09/2015: No new DOI.</p> <p>14/03/2016: No new DOI.</p>	<p>Personal financial non-specific</p> <p>Nil</p> <p>Nil</p> <p>Personal non-financial specific</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p>	<p>Declare and participate</p> <p>Nil</p> <p>Nil</p> <p>Declare and participate</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p>
Gerri Mortimore	Lead CNS Liver, Derby Hospitals NHS Foundation Trust	<p>11/07/2014: None declared</p> <p>04/09/2014: Apologies received.</p> <p>17/10/2014: No new DOI.</p> <p>26/11/2014: Apologies received.</p> <p>21/01/2015: No new DOI.</p>	<p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p>	<p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p>

Committee membership list – cirrhosis guideline Committee

		<p>18/02/2015: No new DOI.</p> <p>26/03/2015: No new DOI.</p> <p>30/04/2015: No new DOI.</p> <p>25/06/2015: No new DOI.</p> <p>29/07/2015: No new DOI.</p> <p>02/09/2015: Apologies received.</p> <p>14/03/2016: Apologies received.</p>	<p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p>	<p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p> <p>Nil</p>
John O'Grady	Professor of Hepatology, King's College Hospital	<p>At recruitment: None declared.</p> <p>30/04/2015: No new DOI.</p>	<p>Nil</p> <p>Nil</p>	<p>Nil</p> <p>Nil</p>
Rachel Pryke	General Practitioner Partner, Winyates Health Centre, Redditch	<p>At recruitment: Speaker fee for attending RCGP Conference 2 October 2014 in order to man a stand on bariatric surgery in conjunction with RCGP Nutrition Group and BOMSS, funded by Ethicon. The stand focuses on bariatric surgery care and post-surgical follow up.</p> <p>21/01/2015: No new DOI.</p>	<p>Personal financial non-specific</p> <p>Nil</p>	<p>Declare and participate (as a co-optee)</p> <p>Nil</p>
Valerie Ross	Lead Pharmacist Hepatology, Barts Health NHS Trust	<p>At recruitment: Has contributed to advisory boards for Janssen relating to the marketing of drugs for hepatitis C within the last 12 months.</p> <p>At recruitment: Has contributed to advisory boards for Gilead relating to the marketing of</p>	<p>Personal financial non-specific</p> <p>Personal financial non-specific</p>	<p>Declare and participate</p> <p>Declare and participate</p>

Committee membership list – cirrhosis guideline Committee

	<p>drugs for hepatitis C within the last 12 months. Payment received including travel expenses.</p> <p>At recruitment: Gave a presentation at a Bristol-Myers Squibb training day on 14 July 2014. Presented on background to the role and responsibilities of the pharmacist in the treatment of HCV and the managed entry of new therapies in this area.</p>	Personal financial non-specific	Declare and participate
	<p>At recruitment: Attended British Association for the Study of the Liver meeting in Newcastle on 15 to 17 September 2014. Janssen funded reduced conference attendance fee, travel, accommodation and subsistence.</p>	Personal financial non-specific	Declare and participate
	11/07/2014: No new DOI.	Nil	Nil
	04/09/2014: No new DOI.	Nil	Nil
	17/10/2014: Apologies received.	Nil	Nil
	26/11/2014: No new DOI.	Nil	Nil
	21/01/2015: No new DOI.	Nil	Nil
	18/02/2015: No new DOI.	Nil	Nil
	26/03/2015: Funding for travel and accommodation	Personal financial non-specific	Declare and participate

Committee membership list – cirrhosis guideline Committee

		<p>received from Abbvie to attend European Association for the Study of the Liver conference in April 2015.</p> <p>26/03/2015: Attended an advisory board for AbbVie.</p> <p>30/04/2015: No new DOI.</p> <p>25/06/2015: No new DOI.</p> <p>29/07/2015: Was a QiC Hepatitis Projects Judging panel member, sponsored by Gilead and Bristol-Myers Squibb on 14 July 2015.</p> <p>29/07/2015: Was a presenter/facilitator at a Bristol-Myers Squibb sponsored nurse training day on 31 July 2015.</p> <p>02/09/2015: No new DOI.</p> <p>14/03/2016: Apologies received.</p>	<p>Personal financial non-specific</p> <p>Nil</p> <p>Nil</p> <p>Personal financial non-specific</p> <p>Personal financial non-specific</p> <p>Nil</p> <p>Nil</p>	<p>Declare and participate</p> <p>Nil</p> <p>Nil</p> <p>Declare and participate</p> <p>Declare and participate</p> <p>Nil</p> <p>Nil</p>
Roy Sherwood	Professor of Clinical Biochemistry, King's College London	<p>At recruitment: None declared.</p> <p>21/01/2015: Receives a salary from the Pathology Department at King's College London which, as of 1 January 2015, is a private company (Viapath).</p>	Personal financial specific	Declare and participate (as a co-optee)

Committee membership list – cirrhosis guideline Committee

Date last reviewed: 06/07/2016